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Abstract
The next-generation sequencing studies of breast cancer have reported that the tumour sup-
pressor P53 (TP53) gene is mutated in more than 40% of the tumours. We studied the levels of
oxidative lesions, including 8-oxo-7,8-dihydro-20-deoxyguanosine (8-oxodG), along the coding
strand of the exon 5 in breast cancer patients as well as in a reactive oxygen species (ROS)-
attacked breast cancer cell line using the ligation-mediated polymerase chain reaction tech-
nique. We detected a significant ‘in vitro’ generation of 8-oxodG between the codons 163 and
175, corresponding to a TP53 region with high mutation prevalence, after treatment with xan-
thine plus xanthine oxidase, a ROS-generating system. Then, we evaluated the occurrence of
oxidative lesions in the DNA-binding domain of the TP53 in the core needle biopsies of 113 of
women undergoing breast investigation for diagnostic purpose. An increment of oxidative dam-
age at the G residues into the codons 163 and 175 was found in the cancer cases as com-
pared to the controls. We found significant associations with the pathological stage and the
histological grade of tumours. As the major news of this study, this largest analysis of genomic
footprinting of oxidative lesions at the TP53 sequence level to date provided a first roadmap de-
scribing the signatures of oxidative lesions in human breast cancer. Our results provide evi-
dence that the generation of oxidative lesions at single nucleotide resolution is not an event
highly stochastic, but causes a characteristic pattern of DNA lesions at the site of mutations in
the TP53, suggesting causal relationship between oxidative DNA adducts and breast cancer.
VC The Author 2016. Published by Oxford University Press on behalf of Kazusa DNA Research Institute.
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1. Introduction
Breast cancer is the most common cancer occurring in women,1 affect-
ing approximately one in eight women during their lifetime.2 So far, a
number of risk factors of breast cancer have been discovered, includ-
ing reproductive and hormonal factors, family history of breast cancer,
alcohol consumption, obesity and overweight.3 Knowledge of how
such risk factors induce cancer is not well defined, but it appears that
an excessive generation of reactive oxygen species (ROS) is associated
to increased breast cancer risk.4–6 ROS are highly reactive intermedi-
ates, which cause various kind of oxidative DNA lesions, including 8-
oxo-7,8-dihydro-20-deoxyguanosine (8-oxodG) and 3-(2-deoxy-b-D-
erythropentafuranosyl)pyrimido[1,2-a]purin-10(3H)-one–deoxygua-
nosine adducts,7 important hallmarks in carcinogenesis.8 The central
question is whether oxidative DNA adducts, in the breast, truly cause
cancer. If so, lowering them would reduce the incidence of breast can-
cer. Conversely, whether the oxidative lesions are caused by tumour
progression, and thereby they are just a bystander, so reducing their
frequency would not truly lower cancer risk.
One of the central pieces of the genome that is often damaged in
cancer cells is the tumour suppressor P53 (TP53), involved in the cell
cycle arrest, DNA repair, senescence and apoptosis.9 Inactivating mu-
tations in the TP53 are the main genetic events in the sporadic cancers
with the vast majority arising from a single point mutation in the seg-
ment encoding the DNA-binding domain of the TP53.10 Somatic
TP53 mutations have been detected in almost every type of sporadic
cancers at rates from 38% to 50%11 and the first next-generation se-
quencing studies of breast cancer have found that the TP53 is mutated
in more than 40% of the tumours.12 Nevertheless, William Thilly has
shown that mutation spectra can vary with dose and thereby such
spectra are limited in the ability to define their origins. Also, people are
always exposed to mixtures of environmental carcinogens.
Genotoxic carcinogens, including ROS, are known to produce
characteristic patterns of somatic mutations in the DNA of malig-
nant cells, which are generally preceded by the generation of charac-
teristic patterns of DNA lesions at the site of mutations, as
exemplified by the 8-oxodG, that, if unrepaired, may result in G:C to
T:A transversions and, at lesser extent, in G:C to AT transitions.8,13
Somatic mutation theory may explain how DNA lesions in genomic
DNA lead to the malignant transformation of cells. The ligation-me-
diated polymerase chain reaction (LMPCR) assay is a method of
choice for the genomic footprinting of human genomic DNA,14 be-
cause it can be used to quantitatively investigate single-strand DNA
breaks having phosphorylated 50-ends within single-copy DNA
sequences.
Our current aims were to investigate whether cancer related genes
have altered frequencies of oxidative lesions in cancer susceptibility
regions and to evaluate whether oxidative DNA adducts truly cause
breast cancer. We examined the levels of oxidative DNA lesions, in-
cluding of 8-oxodG, along the coding strand of the exon 5 of the
TP53 in MDA-MB23 oestrogen receptor negative (ER) breast cells
after treatment with xanthine plus xanthine oxidase, a ROS-generat-
ing system. The genomic footprinting was performed using the
LMPCR technique15 with some modifications accordingly to Davies
and Murray.16 The enzymatic cleavage of DNA was obtained by the
treatment with formamidopyrimidine DNA glycosylase (Fpg) and
endonuclease III (EndoIII), two Escherichia coli repair enzymes that
recognize various types of oxidative damage.17,18 The generation of
oxidative DNA damage in the experimental cells was also analysed
using the 32P-postlabelling technique.19 Next, we conducted a hospi-
tal-based study for evaluating the occurrence of oxidative DNA le-
sions at the TP53 sequence level in the core needle biopsies of 113 of
women undergoing breast investigation for diagnostic purpose.
2. Materials and methods
2.1. Cell culture and DNA isolation
The MDA-MB23 ER breast cells were grown under standard con-
ditions in a 5% CO2 humidified incubator and treated at 30–40%
confluence with 0.2 mM xanthine plus 1.0 or 5.0 mU xanthine oxi-
dase for 24 h. DNA was isolated using a method requiring RNase
and proteinase treatments and extraction with organic solvents.20
After DNA concentration and purity determination, coded samples
were stored at 80 C.
2.2. Study population
Breast cancer cases and controls were recruited among women un-
dergoing breast investigation for diagnostic purpose at the Senology
Unit. After being informed of the purpose of the study and signed an
informed written consent, core needle biopsies were collected under
radiographic guidance by interventional radiologists, snap-frozen
and stored at 80C until laboratory analysis. A questionnaire was
completed by each participant after biological sampling collection.
Histopathological diagnosis and laboratory test findings were ob-
tained from the Pathological Anatomy Unit. Study procedures were
performed in accordance with the guidelines of the General Hospital
Institutional Committee that reviewed and approved the protocol.
2.3. Ligation-mediated polymerase chain assay
The levels of oxidative lesions have been analysed along the exon 5
using the LMPCR technique15 with some modifications.16 The melt-
ing temperatures (Tm) of the primers were calculated by the method
of the nearest-neighbor,21 according to Allawi and SantaLucia.22
2.3.1. Enzymatic cleavage
DNA template (2 mg, 0.4 mg/ml) was incubated with a mix of reaction
buffer (10 ), 0.4 U Fpg (0.2 U/ml) and 200 U EndoIII (100 U/ml) at
37 C for 60 min (final volume 10 ml) to create fragments with 50-
phosphate groups at the sites of DNA lesions.
2.3.2. Primer extension
The fragments containing ligatable breaks were amplified with
16.0 pmol of a primer with the following sequence 50-
GGCAACCAGCCCTGTCG and a calculated Tm of 56 C, in a mix
of 3 U Thermococcus litoralis exo- (Vent exo-) DNA polymerase
(2 U/ml),23 0.6 mM dNTPs and 0.5 mM MgSO4. The following pro-
gram was performed: denaturation at 95 C for 2 min, annealing at
54 C for 2 min and elongation at 72 C for 2 min (1 cycle) followed
by 20 cycles of 1 min at 95 C, 2 min at 54 C and 3 min at 72 C.
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2.3.3. Overnight ligation
The blunt ended fragments with 50-phosphate termini were overnight
incubated with a mix of ligase buffer (10), 0.05 mg/ml bovine se-
rum albumin (added as 10 mg/ml), 60 pmol of the asymmetric dou-
ble-stranded unphosphorylated linker, and 90 U T4 ligase (400 U/ml)
at 17 C (final volume 30ll) for generating a common sequence at
all 50-ends. After ligation, the linker-ligated fragments were evapo-
rated to dryness under reduced pressure in a speed-vacuum concen-
trator and resuspended in 10ll of ultrapure water.
2.3.4. PCR amplification and labelling
PCR amplification has been combined with direct labelling according
to Davies and Murray.16 The amplification and labelling reactions
were achieved with 12.0 pmol of a IRDyeVR 700/800 fluorescence-
labelled primer with the following sequence 50-TCTCTCCAGCCCC
AGCTGCTCAC and a calculated Tm of 61 C and 12.0 pmol of the
LP25 universal linker primer in a mix of 1 U of Vent exo- (2 U/ll),
0.3 mM dNTPs and 2.5 mM MgSO4. The following PCR conditions
were utilized: denaturation at 95 C for 2 min (1 cycle), followed by
10 cycles of 45 s at 95 C, 3 min at 59 C and 3 min at 72 C.
2.3.5. Detection and quantification
The IRDyeVR 700/800 fluorescence-labelled products (2 ml) were
denaturated with formamide loading buffer (3 ml) at 95 C for 5 min
(final volume 5ml), and, after 10 min on ice, denaturated labelled
products (1 ml) were subjected to electrophoresis on a polyacrylamide
sequencing gel, 80.0% acrylamide, 10% bis-acrylamide/urea and
run in the LI-COR 4300 DNA analyzer at 65 C for 7 h. DNA le-
sions were identified as the locations in which the presence of Fpg
and EndoIII-sensitive sites stopped the Vent exo- from progressing
and resulted in an intense dark band. The relative band intensity
(RI), quantificated by ImageQuant, were calculated by following for-
mula RI¼ Ij/Imax, where Ij is the intensity in pixels of each band after
background subtraction and Imax is the mean intensity in pixels of
the highest intensity bands.24 The RI values were corrected across ex-
periments based on the recovery of the reference standard. The exact
position of each base was determined by including labelled DNA
fragments obtained by sequencing of the region of interest according
to Ruano and Kidd25 and appropriate size IRDyeVR 700/800 sizing
standards markers in the sequencing gel.
2.4. 32P-DNA postlabelling assay
The levels of 3-(2-deoxy-b-D-erythro-pentafuranosyl)pyrimido
[1,2-a]purin-10(3H)-one deoxyguanosine (M1dG) adducts in the ex-
perimental cells were measured using a version of the 32P-DNA post-
labelling assay,19 that has been developed for the specific detection
of M1dG adducts.
26 The levels of DNA damage were expressed as
relative adduct labelling ¼pixels in adducted nucleotides/pixels in
normal nucleotides. Adduct levels were corrected across experiments
based in the recovery of the reference standard, which has been pre-
pared as previously reported.27
2.5. Statistical analysis
Given the right-skewed distribution of the data, adduct levels were
log-transformed to stabilize the variance and normalize the distribu-
tion. The Mann–Whitney U test was used to compare experimental
groups in the ‘in vitro’ studies. The association of oxidative lesions
with breast cancer was evaluated by the analysis of covariance, in-
cluding terms for age (continuous), menopausal status and smoking
history (non-smokers, current smokers), to estimate the effect of each
variable on the outcome adjusting for the concomitant effect of the
other variables included in the model. The analysis of covariance
was also applied to examine the difference between the levels of oxi-
dative DNA lesions according to the pathological diameter, the histo-
logic cell grade and the frequency of hormonal receptors positive to
oestrogen and progesterone. Post hoc Dunnett tests were performed
for multiple comparisons among variable levels. All statistical tests
were two-sided and P<0.05 has been considered to be statistically
significant. The data were analysed using SPSS 13.0 (IBM SPSS
Statistics, New York, NY).
3. Results
3.1. Xanthine plus xanthine oxidase treatment
To look for the genomic footprints caused by electrophilic com-
pounds in experimental cells treated with the xanthine plus xanthine
oxidase system, we measured the levels of oxidative lesions along the
coding strand of the exon 5 using the LMPCR assay. Figure 1 reports
a representative map of the area with the cluster of oxidative DNA
lesion products at the TP53 sequence level after treatment with
0.2 mM xanthine plus 5.0 mU xanthine oxidase system. The se-
quencing gel shows that various bases were hotspots for oxidative
DNA damage between the codons 163 and 175. Other DNA damage
sites were not observed. After showing the production of DNA dam-
age at the DNA sequence level, we tried to quantify the levels of oxi-
dative lesions at single nucleotide resolution following exposure of
the same cell line to various doses of the ROS-generating system. The
mean levels of oxidative lesions, expressed as RI,24 at selected posi-
tions of representative codons of the TP5311 were reported in
Table 1. Significant dose-response relationships were found at the
–T–and –G– residues into the codons 163, 170, 173 and 175, with
the highest levels of DNA damage in the experimental cells treated
with the highest dosage of the free radical-generating system, and
with the lower levels in those exposed to the intermediate dosage. In
cells without exposure to the xanthine plus xanthine oxidase system,
a background level of oxidative DNA damage was found. The pres-
ence of oxidative damaged DNA in the experimental cells treated
with increased concentration of the xanthine plus xanthine oxidase
system was confirmed by the analysis of M1dG adducts, a biomarker
of oxidative stress and lipid peroxidation,28–30 using the 32P-postlab-
elling technique. We observed that the frequency of M1dG was sig-
nificantly increased within the cells treated with the ROS-generating
system as compared to controls. The mean levels of M1dG adducts 
106 normal nucleotides were 2.8760.59 and 0.3860.10 of the
treated cells and the controls, respectively, P¼0.007 (Table 1). A sig-
nificant dose-response relationship was observed, P-value for
trend<0.001.
3.2. Breast cancer case-control study
The core needle biopsies were obtained from 113 women, average
aged 58.8615.5 yrs. Seventy-three women were confirmed as hav-
ing breast cancer from histopatological analysis. Forty women with
benign breast lesions were considered as controls. Nineteen women
were classified as smokers. Breast cancer case and benign breast dis-
ease groups were comparable in terms of age, 60.6 yrs6 15.0 (S.D.)
vs. 55.7 yrs6 16.1 (S.D.), respectively.
Having validated the use of the LMPCR assay and having showed
that the ROS-generating system can produce highly localized damage
in experimental cells, we tried to quantify the generation of oxidative
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lesions along the coding strand of the exon 5 of the TP53 in the
study population. Our results show that a cluster of oxidative DNA
lesions, including 8-oxodG, was present between the codons 170 and
173. A representative sequencing gel in Fig. 1 shows that specific ba-
ses were consistently hotspots for oxidative DNA damage in the
breast cancer cases as compared to the controls. Other hotspots for
oxidative DNA damage were not observed. The average levels of oxi-
dative lesions, expressed as RI,24 at the levels of selected nucleotides
of representative codons of the TP5311 were reported in Table 2.
Our findings indicate that significant enhancements of the levels of
ATCG
-175 G-
-173 G-
-170 G-
-163 A-
+ + -
Xanthine oxidase Controls senalgnicneuqeslortnoCsesacrecnactsaerB
Figure 1. Representative map of oxidative lesion along the coding strand of the exon 5 of the TP53 of women with breast cancer as compared to controls. MDA-
MB23 ER breast cells treated with 0.2mM xanthine plus 5.0mU xanthine oxidase system and untreated cells were on the left. Control sequencing lanes were
on the right, whereas the numbers and letters to the right represent codon positions.
Table 1. The mean levels of 3-(2-deoxy-b-D-erythro-pentafuranosyl)pyrimido[1,2-a]purin-10(3H)-one deoxyguanosine (M1dG) adducts,
expressed as relative adduct labelling (RAL  106), and the average amounts of oxidative lesions, expressed as relative intensity (RI), at
the TP53 level in the MDA-MB23 oestrogen receptor-negative breast cells treated with increased concentrations of the xanthine plus
xanthine oxidase system
Genomic DNA Oxidative lesions along the coding strand of the exon 5 of the human TP53 gene
M1dG Codon 163 (-TAC-) Codon 170 (-ACG-) Codon 173 (-GTG-) Codon 175 (-CGC-)
N RAL 6 S.E. P-value RI6 S.E. P-value RI6 S.E. P-value RI6 S.E. P-value RI6 S.E. P-value
Experimental dosages
Controlsa 10 0.38 6 0.10 0.08 6 0.02 0.06 6 0.01 0.10 6 0.03 0.11 6 0.03
0.2 mM xanthine, 1.0 mU
xanthine oxidase
10 1.89 6 0.10 0.016 0.10 6 0.02 0.214 0.40 6 0.07 0.016 0.18 6 0.03 0.114 0.19 6 0.03 0.164
0.2 mM xanthine, 5.0 mU
xanthine oxidase
10 2.87 6 0.59 0.007 0.22 6 0.03 0.004 0.55 6 0.08 0.004 0.44 6 0.07 0.005 0.28 6 0.04 0.014
P-value for trend <0.001 0.001 <0.001 0.001 0.012
aReference level.
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8-oxodG into the codons 170 and 173 were detected in the breast
cancer cases as compared to the controls (Table 2). Specifically, the
levels of oxidative lesions at the –T– position into the codon 163 of
the cancer cases and the controls were 0.196 0.02 and 0.156 0.01,
respectively, P¼0.493 after adjusting for age, menopausal status
and smoking history; the values of 8-oxodG at the –G– residue into
the codon 170 of the breast cancer cases and the controls were
0.5160.04 and 0.306 0.02, respectively, P¼0.012 after correc-
tion for the confounding factors; the levels of 8-oxodG at the first
–G – position into the codon 173 of the breast cancer patients and
the controls were 0.446 0.04 and 0.286 0.02, respectively,
P¼0.039 after adjusting for the confounding factors; and the levels
of 8-oxodG at the –G – residue into the codon 175 of the cancer pa-
tients and the controls were 0.236 0.02 and 0.186 0.01, respec-
tively, P¼0.270 after correction for the confounding factors.
When the pathologic stage of the breast tumours was examined,
significant increments of oxidative lesions at the –G– positions into
the codons 170, 173 and 175 with increased pathological stage were
found (Table 2). Significant trends were also observed. In detail, the
levels of oxidative lesions at single nucleotide resolution were
0.4160.11 and 0.156 0.01 at the –T– residue into the codon 163
of the breast cancer cases with a pT3 stage and the controls, respec-
tively, P¼0.062 after adjusting for the confounding factors; the val-
ues of 8-oxodG were 0.766 0.13 and 0.306 0.02 at the –G–
position into the codon 170 of the breast cancer cases with a pT3
stage and the controls, respectively, P¼0.025 after correction for
the confounding factors; the levels of 8-oxodG were 0.736 0.19 and
0.286 0.02 at the first –G– residue into the codon 173 of the breast
cancer patients with a pT3 stage and the controls, respectively,
P¼0.037 after adjusting for the confounding factors; and the
amounts of 8-oxodG were 0.4660.09 and 0.186 0.01 at the –G–
position into the codon 175 of the cancer patients with a pT3 stage
and in the controls, respectively, P¼0.012 after correction for the
confounding factors. Statistically significant relationships were ob-
served at the –G– residues into the codons 170, 173 and 175 with
the highest levels of 8-oxodG in the patients with a pT3 stage, and
intermediate values in those with early stages of cancer (Table 2).
On the other hand, when the histologic cell grade of tumours was
analysed, a statistically significant enhancement of 8-oxodG levels
into the codon 170 was observed with increasing grading (Table 2),
but with the highest levels of DNA damage at the –G– residues into
the codons 173 and 175 in patients with a G2 value. Significant
trends of 8-oxodG generation into the codons 170 and 173 with in-
creasing grade were found (Table 2). In detail, the levels of 8-oxodG
were 0.5460.06, 0.646 0.06 and 0.306 0.02 at the –G– residue
into the codon 170 in the breast cancer cases with G3 and G2 values
and the controls, respectively, P< 0.013 and P<0.001 after correc-
tion for the confounding factors.
Table 2. The mean levels of oxidative lesions at the DNA sequence level, expressed as relative intensity (RI), at selected positions of
representative codons along the coding strand of the exon 5 of the TP53 according to study variables
Oxidative lesions along the coding strand of the exon 5 of the human TP53 gene
Codon 163, (-TAC-) Codon 170 (-ACG-) Codon 173 (-GTG-) Codon 175 (-CGC-)
Na RI6 S.E. P-valueb RI6 S.E. P-valueb RI6 S.E. P-valueb RI6 S.E. P-valueb
Menopausal status
Premenopausalc 43 0.19 6 0.03 0.45 6 0.05 0.41 6 0.05 0.24 6 0.02
Postmenopausal 70 0.16 6 0.01 0.897 0.43 6 0.03 0.928 0.36 6 0.03 0.949 0.20 6 0.01 0.926
Smoking habit
Non-smokersc 94 0.17 6 0.01 0.45 6 0.03 0.38 6 0.03 0.226 0.01
Smokers 19 0.17 6 0.03 0.937 0.39 6 0.06 0.568 0.38 6 0.07 0.738 0.22 6 0.03 0.972
Cancer status
Controlsc 40 0.15 6 0.01 0.30 6 0.02 0.28 6 0.02 0.18 6 0.01
Breast cancer cases 73 0.19 6 0.02 0.493 0.51 6 0.04 0.012 0.44 6 0.04 0.039 0.23 6 0.02 0.270
Pathologic stage of tumour
pT1, tumour 20 mm in greatest dimension 29 0.15 6 0.02 0.997 0.45 6 0.04 0.131 0.40 6 0.05 0.599 0.21 6 0.03 0.996
pT2, tumour >20 mm but 50 mm
in greatest dimension
10 0.16 6 0.05 0.998 0.516 0.08 0.203 0.48 6 0.08 0.182 0.23 6 0.05 0.919
pT3, tumour >50 mm in greatest dimension 5 0.41 6 0.11 0.062 0.76 6 0.13 0.025 0.73 6 0.19 0.037 0.46 6 0.09 0.012
P-value for trend 0.120 0.001 0.003 0.036
Histologic cell grade
G1, well differentiated 9 0.09 6 0.03 0.126 0.28 6 0.07 0.756 0.25 6 0.08 0.525 0.17 6 0.06 0.533
G2, moderately differentiated 21 0.27 6 0.05 0.094 0.64 6 0.06 <0.001 0.61 6 0.07 0.001 0.33 6 0.05 0.025
G3, poorly differentiated 15 0.19 6 0.04 0.797 0.54 6 0.06 0.013 0.48 6 0.09 0.094 0.25 6 0.05 0.612
P-value for trend 0.091 <0.001 0.001 0.072
Oestrogen receptor
Er c 8 0.15 6 0.03 0.40 6 0.09 0.40 6 0.10 0.21 6 0.04
Erþ 56 0.15 6 0.15 0.655 0.45 6 0.04 0.753 0.35 6 0.03 0.417 0.19 6 0.18 0.640
Progesterone receptor
Pr c 13 0.14 6 0.02 0.4360.11 0.43 6 0.09 0.19 6 0.03
Prþ 51 0.15 6 0.01 0.841 0.43 6 0.03 0.707 0.34 6 0.03 0.483 0.20 6 0.01 0.973
aSome figure do not add up to the total because of missing values.
bP-values after adjusting for the confounding factors.
cReference level.
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4. Discussion
4.1. Single nucleotide TP53 lesions and free radicals
We evaluated the genomic footprints caused along the coding strand
of the exon 5 of the TP53, a gene highly mutated in breast cancer,11
from the treatment with increased doses of the xanthine plus xan-
thine oxidase system using the LMPCR technique. The xanthine oxi-
dase is an enzyme, which catalyses the conversion of hypoxanthine
and xanthine into uric acid and uses oxygen as redox partner by pro-
ducing various ROS, including superoxide anion radicals and hydro-
gen peroxide. As result, we observed a significant production of 8-
oxodG between the codons 163 and 175 in the experimental cells
(Fig. 1) corresponding to a region of the TP53 with high mutation
rates.11 The presence of oxidative damage in the experimental cells
treated with the ROS-generating system was confirmed using the
32P-postlabelling technique.19 After treatment with increased concen-
trations of the ROS-generating system, the production of oxidative
lesions was increased of about 9-fold half level (Table 1), supporting
that the damage at single nucleotide resolution results from ROS at-
tack. Overall, our findings presented here indicate that the interac-
tion of electrophilic species with genomic DNA causes the generation
of oxidative DNA damage in a susceptible region along the coding
sequence of the exon 5. Our results are consistent with the previous
reports of Rodriguez et al.31 and Arakawa et al.,24 that analysed the
frequency of oxidative lesions at the TP53 sequence level after hy-
drogen peroxide treatment in ‘in vitro’ studies. In particular,
Arakawa et al. 24 reported that ROS treatment induced a similar pat-
tern of fingerprints of oxidative DNA lesions within the exon 5.
4.2. Single nucleotide TP53 lesions and breast cancer
Having shown the production of base damage at the TP53 sequence
level after ROS attack, we have focused on the largest analysis of ge-
nomic footprinting in humans to date. Our next result provides evi-
dence that the generation of oxidative lesions at single nucleotide
resolution is not an event highly stochastic with an overall low fre-
quency, but causes site-specific DNA damage inducing a characteris-
tic pattern of DNA lesions at the site of mutations in the TP53. This
supports causal relationship between oxidative DNA lesions and
breast cancer. Indeed, as expected, the mapping of the exon 5 indi-
cates the presence of a cluster of oxidative damage between the co-
dons 163 and 175 in the cancer patients as compared to the controls
(Fig. 1). Although codon 175, known as one of the mutation hot
spots in breast cancers,11 also exhibited the highest adduction rate in
the breast cancer cases, no apparent difference is shown regarding
the incidence of oxidative lesions between codons 163 and 175
(Table 2). Taken together, our results show the existence of a cluster
of hotspots of DNA damage at the TP53 sequence level, that can be
explained by a higher susceptibility of particular sites to be attacked
from electrophilic compounds.8 Additionally, the fingerprint map of
the breast cancer patients was comparable to that observed in the ex-
perimental cells treated with the ROS-generating system (Fig. 1). In
particular, the amounts of oxidative damage at the –G– residues into
the codons 170 and 173 were significantly increased in the breast
cancer patients as compared to healthy tissues (Table 2). The fact
that the exon 5 of the TP53 can be targeted to unique sites in the ge-
nome of breast cancer patients will be of considerable value. The in-
creased levels of oxidative DNA damage along the DNA-binding
domain can indeed be considered a cancer risk factor, since if unre-
paired, they can lead to various mutations and subsequently trigger
breast carcinogenesis. This depends on whether the oxidation causes
cancer or the generation of oxidative DNA damage is influenced by
early effects of cancer itself.
4.3. Single nucleotide TP53 lesions and prognostic
factors
Enhanced levels of 8-oxodG at the TP53 sequence level were also sig-
nificantly associated with conventional prognostic factors such as the
pathological stage and the histological grade of breast tumours, indi-
cating that high levels of 8-oxodG may exert detrimental effects dur-
ing cancer development and tumour progression. Nevertheless, the
possibility that ROS act such as a form of endogenous chemotherapy
during tumour progression cannot be excluded. This association was
even more evident at the –G– residue into the codon 170 of the pa-
tients with poorly differentiated tumours of>50 mm dimension
(Table 2). Consistent with our results, a main role for oxidative stress
in the pathogenesis of oestrogen-induced breast cancer has been sug-
gested.32 Earlier studies have discovered augmented levels of bio-
markers of oxidative stress in either urine and tumour tissue
DNA.4,5,33–35 Recently, high 8-oxodG has been associated to subse-
quent risk of breast.5 Also, we have conducted a hospital-based
study to analyse the amount of M1dG, a biomarker of oxidative
stress,29,30,36 in breast cancer patients.4 In that study, we found a sig-
nificant association between M1dG and breast cancer, as well as
with increasing the degree of differentiation and severity of cancer.
Various underlying mechanisms are involved in the generation of ox-
idative DNA lesions, such as the oestrogens,34 that are metabolically
activated into catechol oestrogens from the cytochrome P450 en-
zymes.37 Metabolic redox cycling between catechol oestrogens and
their corresponding quinones can generate oxidative stress and
ROS.34 Chronic inflammation associated to adiposity3 as well acti-
vated inflammatory neutrophils38 can also induce ROS.
4.4. TP53 genomic fooprinting
As the major news of this study, this largest analysis of genomic foot-
printing of oxidative lesions at the TP53 sequence level to date pro-
vided a first roadmap describing the signatures of oxidative lesions in
human breast cancer. Remarkably, our results indicate that the
LMPCR technique15 a versatile DNA-lesion footprinting technique,
which enables sensitive and specific detection of oxidative DNA
damage at the level of sequence resolution, may be used for evaluat-
ing cancer risk in future clinical and epidemiological studies. In par-
ticular, the current LMPCR procedure involved the combination of
PCR amplification with direct labelling developed by Davies and
Murray.16 Furthermore, this system will allow detailed analysis of
the effects of site-specific DNA lesions on cellular functions.
4.5. Single nucleotide TP53 lesions and mutation
prevalence
Data on mutation prevalence in breast cancer may be easily accessed
through the IARC TP53 database,11 therefore, we examined the levels
of oxidative DNA lesions at single nucleotide resolution to the fre-
quencies of mutations in the same positions along the DNA-binding
domain11 in the attempt of evaluating the potential mechanisms un-
derlying the pathogenesis of breast cancer. Table 3 shows that the gen-
eration of oxidative DNA damage along the DNA-binding domain of
the TP53 was found in sites where the prevalence of transversion and
transition mutations was ranging from 0.28% to 4.52%. The occur-
rence of special mutation patterns might suggest of the nature of the
mutagens that have caused them. In this case, the mutation spectra
400 Single nucleotide TP53 lesions in breast cancer
reveal some of the characteristics expected from the effects of ROS ex-
posure on DNA. It was apparent that the generation of 8-oxodG asso-
ciated to the principal mutagenic events generated by this
compound,13 may be in part responsible of the induction of these
TP53 mutations. Theoretically, the colocalization of DNA lesions and
mutational hotspots in the TP53 gene may be used for causality infer-
ence. This interpretation is further strengthened by previous findings
reporting that G:C!T:A tranversions derived from 8-oxodG have
been found in malignant tumours.8 Of course, other models have indi-
cated that the deamination of 5-methylcytosine in methylated CpG se-
quences may be a mechanisms of CpG transitions.39 Interestingly, the
process of 5-methylcytosine deamination may be enhanced by the ex-
posure to ROS, especially in cancers arising from inflammatory pre-
cursors.40 These elements suggest that the present spectra of oxidative
lesions may theoretically account for at least a part a percentage of the
TP53 mutations present in breast tumours.
4.6. Conclusions
The integration of DNA adduct data with cancer mutations, as ex-
emplified in our report, may provide an improved knowledge of the
complex relationship between the TP53 gene and breast cancer de-
velopment and progression. Considering that DNA-lesion footprint-
ing in conjunction with mutation analysis are used to correlate DNA
damage and mutagenesis and to demonstrate causality inference, we
may argue that oxidative lesions occurring at the –G– residues into
the codons 170 and 173 might serve as a necessary hit required to
drive the process of breast carcinogenesis and tumour progression.
Our study provides evidence that the production of oxidative lesions
at the TP53 sequence level is not an event stochastic, but induce a
characteristic spectrum of DNA adducts at the site of mutations, sup-
porting causal relationship between oxidative DNA lesions and
breast cancer. Also, the data suggest the possibility that the level of
oxidative DNA lesions may be a prognostic factor in breast cancer.
Analysing the generation of DNA damage at single nucleotide resolu-
tion will serve as a foundation for future work examining the mecha-
nisms of oxidative DNA damage in breast carcinogenesis.
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